1. Home
  2. SYBX vs NCRA Comparison

SYBX vs NCRA Comparison

Compare SYBX & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • NCRA
  • Stock Information
  • Founded
  • SYBX N/A
  • NCRA 2002
  • Country
  • SYBX United States
  • NCRA Taiwan
  • Employees
  • SYBX N/A
  • NCRA N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • NCRA Farming/Seeds/Milling
  • Sector
  • SYBX Health Care
  • NCRA Consumer Staples
  • Exchange
  • SYBX Nasdaq
  • NCRA Nasdaq
  • Market Cap
  • SYBX 16.5M
  • NCRA 16.8M
  • IPO Year
  • SYBX N/A
  • NCRA N/A
  • Fundamental
  • Price
  • SYBX $1.20
  • NCRA $1.01
  • Analyst Decision
  • SYBX
  • NCRA
  • Analyst Count
  • SYBX 0
  • NCRA 0
  • Target Price
  • SYBX N/A
  • NCRA N/A
  • AVG Volume (30 Days)
  • SYBX 6.3K
  • NCRA 20.2K
  • Earning Date
  • SYBX 03-06-2025
  • NCRA 05-14-2025
  • Dividend Yield
  • SYBX N/A
  • NCRA N/A
  • EPS Growth
  • SYBX N/A
  • NCRA N/A
  • EPS
  • SYBX N/A
  • NCRA N/A
  • Revenue
  • SYBX $8,000.00
  • NCRA $20,483,694.00
  • Revenue This Year
  • SYBX N/A
  • NCRA N/A
  • Revenue Next Year
  • SYBX N/A
  • NCRA N/A
  • P/E Ratio
  • SYBX N/A
  • NCRA N/A
  • Revenue Growth
  • SYBX N/A
  • NCRA N/A
  • 52 Week Low
  • SYBX $1.15
  • NCRA $0.70
  • 52 Week High
  • SYBX $1.96
  • NCRA $2.09
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 34.47
  • NCRA 51.54
  • Support Level
  • SYBX $1.27
  • NCRA $0.96
  • Resistance Level
  • SYBX $1.32
  • NCRA $1.14
  • Average True Range (ATR)
  • SYBX 0.05
  • NCRA 0.09
  • MACD
  • SYBX -0.01
  • NCRA -0.00
  • Stochastic Oscillator
  • SYBX 17.81
  • NCRA 38.71

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

Share on Social Networks: